{
  "docId": "019de075-f745-744d-a2c3-62fcecd316e9",
  "docSlug": "352ee416e6a97a9b39e1309fafdab0f3",
  "documentTitle": "Genelux | Investor Presentation Deck | 38 slides",
  "authorId": "genelux",
  "authorName": "Genelux",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 38,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "The chart compares cross-trial data; the footnote explicitly warns against direct comparison due to protocol differences.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-f745-744d-a2c3-62fcecd316e9/17",
  "deckHref": "/decks/019de075-f745-744d-a2c3-62fcecd316e9",
  "deckJsonHref": "/decks/019de075-f745-744d-a2c3-62fcecd316e9.json",
  "deckAnchorHref": "/decks/019de075-f745-744d-a2c3-62fcecd316e9#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.58,
        "x": 0.365,
        "y": 0.245
      },
      "kind": "chart",
      "text": "Comparative efficacy chart across RECIST1.1, CA-125, and PFS-6-month metrics.",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c6b807a4-369c-4c0d-ba7c-556344cdb04a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.29,
        "x": 0.045,
        "y": 0.31
      },
      "kind": "list",
      "text": "Olvi-Vec trial inclusion criteria allows patients regardless of (i) tumor biomarkers, (ii) platinum refractory tumors, or (iii) number of prior lines of treatment (i.e., no cap). Olvi-Vec Phase 2 results approach results in less pre-treated platinum-sensitive patients",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1ec7e18f-7087-4a5a-93ce-47dea08c52da",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.56,
        "x": 0.38,
        "y": 0.15
      },
      "kind": "paragraph",
      "text": "While clinical remissions are obtainable, a majority of patients will relapse. Genelux looks to take an all-comers approach",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6ae36887-2231-4705-81e4-09e7815b2f16",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.58,
        "x": 0.365,
        "y": 0.8
      },
      "kind": "source-note",
      "text": "References (1)-(6) and disclaimer footnote regarding cross-trial comparison limitations.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f1eed1ea-727e-478c-b2ff-9a8271d69d24",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.58,
        "x": 0.365,
        "y": 0.47
      },
      "kind": "table",
      "text": "Study comparison table listing prior lines of treatment and regimens for various clinical trials.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fe0b1d69-09c3-4387-945a-7f71f31fdb1e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.94,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "“Allcomers” Approach May Reset Life Clock of Heavily Pre-treated Patients",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "18993078-2d9e-4ef6-93ec-c97c0b2f4571",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Audience Definition",
      "slug": "audience-definition",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "8a3c282d-8ac3-4e52-a6d1-ef4c0c5be02c",
      "evidence": "Olvi-Vec addresses a broad and underserved pool of patients",
      "confidence": 0.7
    },
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "fe0ebe8f-6ecf-4c2a-9bd1-8ee92844061d",
      "evidence": "Olvi-Vec trial inclusion criteria allows patients regardless of (i) tumor biomarkers, (ii) platinum refractory tumors, or (iii) number of prior lines of treatment",
      "confidence": 0.6
    }
  ],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "9d4f2f6c-85ac-4606-884a-f2e3809fc5ad",
      "evidence": "Comparative bar chart and table against industry peers",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 38,
      "from": 10,
      "beatId": "523d1cf4-1cd0-4572-8561-e435ff7a2275",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 10-38 present Olvi-Vec as a solution, detailing its competitive advantages, clinical results, and market potential.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}